| Recruiting | A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD) NCT07016802 | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormon NCT04867317 | VA Office of Research and Development | Phase 3 |
| Not Yet Recruiting | BELux Children OutcoME During A(@)Dulthood With GHD NCT06694506 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | N/A |
| Recruiting | Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT) NCT05355272 | Baylor College of Medicine | Phase 2 |
| Unknown | The Effects of Growth Hormone Treatment Discontinuation in Adults on Metabolic Profile, Body Composition and Q NCT05979480 | University Hospital Birmingham | — |
| Enrolling By Invitation | A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Saf NCT05718570 | Novo Nordisk A/S | — |
| Active Not Recruiting | Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya® NCT05230550 | Novo Nordisk A/S | — |
| Completed | A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Defici NCT05171855 | Ascendis Pharma Endocrinology Division A/S | Phase 3 |
| Completed | Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan NCT03212131 | Novo Nordisk A/S | Phase 1 |
| Completed | Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan NCT03186495 | Novo Nordisk A/S | Phase 1 |
| Unknown | A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD NCT03104010 | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® Flex NCT03075644 | Novo Nordisk A/S | Phase 3 |
| Completed | Versartis International Trial in Adults With Long-Acting Growth Hormone NCT02526420 | Versartis Inc. | Phase 2 |
| Completed | A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Wee NCT02382939 | Novo Nordisk A/S | Phase 3 |
| Completed | A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9 NCT02946606 | Genexine, Inc. | Phase 2 |
| Completed | Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® NCT02229851 | Novo Nordisk A/S | Phase 3 |
| Completed | Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone NCT02005198 | Novo Nordisk A/S | — |
| Completed | An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Ad NCT01806298 | Merck KGaA, Darmstadt, Germany | Phase 4 |
| Terminated | A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Def NCT01909479 | OPKO Health, Inc. | Phase 3 |
| Completed | A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long- NCT01706783 | Novo Nordisk A/S | Phase 1 |
| Completed | First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects NCT01514500 | Novo Nordisk A/S | Phase 1 |
| Completed | Safety and Efficacy Study of Recombinant Human Growth Hormone in Adult Growth Hormone Deficiency Patients NCT01822340 | Hanmi Pharmaceutical Company Limited | Phase 2 |
| Completed | The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis NCT01282164 | The Cleveland Clinic | N/A |
| Completed | A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone De NCT01247675 | Ascendis Pharma A/S | Phase 2 |
| Completed | MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA) NCT01225666 | OPKO Health, Inc. | Phase 2 |
| Completed | Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficienc NCT01109017 | Novo Nordisk A/S | — |
| Completed | An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditrop NCT00934063 | Novo Nordisk A/S | — |
| Completed | Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of N NCT00715689 | Novo Nordisk A/S | Phase 2 |
| Completed | Treatment of Adults With Growth Hormone Deficiency NCT00596037 | LG Life Sciences | Phase 3 |
| Completed | Observational Prospective Study on Patients Treated With Norditropin® NCT00960128 | Novo Nordisk A/S | — |
| Completed | Treatment of Adults With Growth Hormone Deficiency NCT00294619 | LG Life Sciences | Phase 3 |
| Completed | Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth NCT00297713 | Altus Pharmaceuticals | Phase 2 |
| Completed | Long-term Trial on Growth Hormone Deficiency in Adults (GHDA) NCT00184730 | Novo Nordisk A/S | Phase 3 |
| Completed | Long-term Trial on Growth Hormone Deficiency in Adults (GHDA) NCT00184743 | Novo Nordisk A/S | Phase 3 |
| Completed | Metabolic Endocrinology and Growth Hormone in Adults NCT01080755 | Merck KGaA, Darmstadt, Germany | — |
| Completed | French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin NCT01580605 | Novo Nordisk A/S | — |
| Completed | Safety and Efficacy of Long-term Somatropin Treatment in Adults NCT01543880 | Novo Nordisk A/S | — |
| Completed | Growth Hormone Deficiency in Adults (GHDA) NCT00519558 | Novo Nordisk A/S | Phase 3 |
| Completed | Extension Study on Safety of Long-Term Growth Hormone Replacement in Adult Patients With Growth Hormone Defici NCT00191360 | Eli Lilly and Company | Phase 3 |
| Completed | Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone Deficien NCT00184678 | Novo Nordisk A/S | Phase 3 |
| Terminated | Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency NCT01698944 | Novo Nordisk A/S | Phase 4 |
| Completed | A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatrop NCT00931476 | Novo Nordisk A/S | Phase 1 |
| Completed | Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients NCT01562834 | Novo Nordisk A/S | Phase 4 |